FogPharma is a technology company.
FogPharma has raised $440.0M across 3 funding rounds.
Key people at FogPharma.
FogPharma has raised $440.0M in total across 3 funding rounds.
FogPharma has raised $440.0M in total across 3 funding rounds.
FogPharma's investors include Lux Capital, Nextech Invest, The Column Group, venBio.
Parabilis Medicines (formerly FogPharma) is a clinical-stage biopharmaceutical company pioneering Helicon™ therapeutics, a novel class of stabilized helical peptide drugs designed to target previously undruggable proteins, primarily for cancer treatment.[1][2][3][6] It serves patients with solid tumors like colorectal cancer (CRC) by addressing limitations of conventional precision medicines through its AI- and physics-integrated discovery platform, which accelerates drug development against intractable targets such as the β-catenin:TCF interaction.[1][3][8] The company's lead candidate, FOG-001, is in Phase 1/2 trials as the first direct inhibitor of this pathway, with additional programs in protein degraders and radioligand therapies; it has raised over $145 million in recent financing, signaling strong growth momentum amid a booming radiopharma sector.[3][4][5][8]
Founded in 2016 (with some sources noting 2015) by Greg Verdine, Ph.D., a pioneer in drugging undruggable targets, FogPharma emerged from Verdine's vision to create cell-penetrating miniproteins (CPMPs) and Helicons—short, helix-shaped amino acid chains that overcome barriers of traditional small-molecule and biologic drugs.[1][2][7][8] Early traction came from assembling a powerhouse team, including experts in cancer biology and AI, backed by a syndicate of top investors; pivotal moments include becoming a Fierce 15 winner in 2023, a $145 million financing in 2024, and a $178 million Series D.[5][8] In 2025, the company rebranded to Parabilis Medicines to reflect its expanded ambitions in AI-driven discovery and global patient reach, while advancing FOG-001 into clinical enrollment for CRC and other solid tumors just 16 months post-discovery.[3][6][8][9]
Parabilis rides the radiopharma and precision oncology boom, where demand for tumor-targeted radiation therapies is surging due to successes like Novartis' Pluvicto, drawing billions in VC and Big Pharma acquisitions.[4] Timing is ideal amid AI's rise in biotech, enabling faster targeting of undruggable proteins—a market force favoring platforms like Helicons over legacy small molecules, especially for solid tumors resistant to immunotherapy.[1][3][4] By influencing the ecosystem through collaborations (e.g., Artbio for Pb-212 radiopharma) and redefining "druggability," Parabilis expands the therapeutic universe, potentially reshaping cancer treatment paradigms and inspiring hybrid peptide-radioligand innovations.[4][6]
Parabilis is poised to advance FOG-001 toward pivotal data in CRC/solid tumors, expand its four late-stage discovery programs, and deepen AI enhancements for degraders and radiopharmas, leveraging its $145M+ war chest.[3][4][5] Trends like AI-biophysics fusion and short half-life isotopes (e.g., Pb-212 for precise imaging) will propel growth, with potential Big Pharma partnerships amplifying influence amid oncology M&A fervor.[4][8] As it evolves from FogPharma's helix vision to a global patient-focused powerhouse, Parabilis exemplifies how targeted innovation achieves universal druggability, delivering years to life for intractable cancers.[2][9]
Key people at FogPharma.
FogPharma has raised $440.0M across 3 funding rounds. Most recently, it raised $150.0M Series E in February 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Feb 1, 2024 | $150.0M Series E | Lux Capital, Nextech Invest, The Column Group, venBio | |
| Nov 1, 2022 | $180.0M Series D | Nextech Invest, venBio | |
| Jan 1, 2021 | $110.0M Series C | Nextech Invest, venBio |
